Recently, OptumRx, a subsidiary of US healthcare giant UnitedHealth Group updated their OptumRx mobile app: https://play.google.com/store/apps/details?id=com.optum.rx&hl=en_AU
In essence, this app is equivalent to MedAdvisor's app.
This leads to two questions...
Are MedAdvisor's US prospects as good as purported or a mere fantasy construed by a company facing the bleak reality of market saturation?
What happens when OptumRx, or a similar product developed by a company in a much stronger financial condition than MedAdvisor (think Express Scripts, CVS Health) enters the Australian market?
Mr Robert Read, your clock is ticking...
Recently, OptumRx, a subsidiary of US healthcare giant...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.030(8.00%) |
Mkt cap ! $190.2M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 37.5¢ | 34.5¢ | $299.2K | 815.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 16289 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 5898 | 2 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| MDR (ASX) Chart |